TCGA-DK-A3X1-01A-12R-A22U-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 65.99868594
- os_event
- false
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.420
- KRAS_SIGNALING_DN+0.320
- ANGIOGENESIS+0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.200
- SPERMATOGENESIS+0.130
- COAGULATION+0.110
- BILE_ACID_METABOLISM+0.060
- KRAS_SIGNALING_UP+0.040
- ESTROGEN_RESPONSE_LATE+0.010
- MYOGENESIS+0.000
Top 10 suppressed
- MYC_TARGETS_V1-0.540
- INTERFERON_ALPHA_RESPONSE-0.490
- MITOTIC_SPINDLE-0.490
- UNFOLDED_PROTEIN_RESPONSE-0.480
- PI3K_AKT_MTOR_SIGNALING-0.470
- OXIDATIVE_PHOSPHORYLATION-0.430
- PROTEIN_SECRETION-0.390
- MTORC1_SIGNALING-0.380
- MYC_TARGETS_V2-0.380
- DNA_REPAIR-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG923 | — | — | 0.943 |
| 2 | MNG90 | — | — | 0.942 |
| 3 | TCGA-DK-A1A7-01A-11R-A13Y-07 | — | — | 0.940 |
| 4 | TCGA-CF-A3MI-01A-11R-A20F-07 | — | — | 0.934 |
| 5 | SRR1500405 | GTEX | — | 0.933 |
| 6 | MNG597 | — | — | 0.933 |
| 7 | TCGA-DK-A3IK-01A-32R-A21D-07 | — | — | 0.933 |
| 8 | TCGA-CF-A3MF-01A-12R-A21D-07 | — | — | 0.930 |
| 9 | msclc569389_S35.txt | — | cohortMD1 | 0.930 |
| 10 | MNG1118 | — | — | 0.929 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.420 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.320 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| COAGULATION | 0.110 | Binimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.040 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.010 | Idelalisib | — uncovered |